Desidustat in the Treatment of Anemia in CKD

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 588 participants.

Also called NCT04012957

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 588 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04012957
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
India (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04012957. Randomized; no masking; primary purpose treatment. Start 2019-07-20 (actual); primary completion 2021-08-25 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Desidustat in the Treatment of Anemia in CKD
Acronym
DREAM-ND
Condition
Chronic Kidney Disease Stage 3
Condition
Anemia
Condition
Chronic Kidney Disease Stage 4
Condition
Chronic Kidney Disease Stage 5
Intervention (Drug)
Desidustat Oral Tablet
Intervention (Drug)
Darbepoetin Alfa
Lead sponsor
Zydus Lifesciences Limited (class: industry)

Record details

Record id
cardio:ct-nct04012957
Content hash
81f9df36eff308a9dadf12e40963c6be0e8935f016231e4b8fec4efae027e0f0